Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile
about
Physiological and Pharmacological Roles of FGF21 in Cardiovascular DiseasesThe FGF21-adiponectin axis in controlling energy and vascular homeostasisEndocrine FGFs: Evolution, Physiology, Pathophysiology, and PharmacotherapyFGF21 and Cardiac PhysiopathologyFibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders.Roles of FGF Signals in Heart Development, Health, and DiseaseFibroblast growth factors in cardiovascular disease: The emerging role of FGF21Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in ChineseSerum CXCL16 as a novel marker of renal injury in type 2 diabetes mellitusCirculating complement-C1q TNF-related protein 1 levels are increased in patients with type 2 diabetes and are associated with insulin sensitivity in Chinese subjectsElevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults.FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and DiseasesSerum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patientsHigh plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjectsAssociation between Serum Fibroblast Growth Factor 21 and Coronary Artery Disease in Patients with Type 2 Diabetes.Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice.Serum Level of Fibroblast Growth Factor 21 Is Independently Associated with Acute Myocardial Infarction.FGF21 protects against ox-LDL induced apoptosis through suppressing CHOP expression in THP1 macrophage derived foam cells.Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes.Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging.Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults.Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic DiseasesEndocrine fibroblast growth factor FGF19 promotes prostate cancer progressionAssociation of metabolic syndrome with serum fibroblast growth factor 21 in kidney transplanted patients.Additive relationship between serum fibroblast growth factor 21 level and coronary artery diseaseFGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders.Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives.Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases.Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.Murine Experimental Model of Original Tumor Development and Peritoneal Metastasis via Orthotopic Inoculation with Ovarian Carcinoma Cells.Fibroblast growth factor 21: a regulator of metabolic disease and health span.Pancreatic Islet Responses to Metabolic Trauma.Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.Cardiac actions of fibroblast growth factor 23.The metabolic hormone FGF21 is associated with endothelial dysfunction in hemodialysis patients.Epicardial fat, body mass index, and triglyceride are independent contributors of serum fibroblast growth factor 21 level in obese premenopausal women.The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension.Decreased expression of Klotho in cardiac atria biopsy samples from patients at higher risk of atherosclerotic cardiovascular diseaseFibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis.
P2860
Q26744232-37E3F874-AA83-44BE-A20D-4A515A30DE62Q26753369-885EEE49-5284-465C-B1FF-B2480AC19B59Q26781556-DAC65D02-CE93-4E90-BE1C-38FBFCAA673DQ26784524-815A39EC-4F80-4DFD-81F3-9A686A5F5029Q27686803-411EA004-A752-4BBD-8579-17EA085EB077Q28072691-3D941DED-21C3-4D8B-9717-732BC5E93AA9Q28084197-99F64AE1-950F-47D8-A6E3-9D0A00385149Q28477784-93EC1927-637A-4BD4-BF1E-0EE140908DC5Q28539322-F96860AE-D322-421E-8D97-70EDE31CB6DCQ33679354-93C853EF-FF19-4DFC-8707-628CEB027577Q33764675-4812BEB3-5E95-443A-A843-45499D8AF066Q33851027-89CA9435-32E7-4EDD-AD6A-8BDAE445CFFBQ35176887-665D8787-EA92-4101-B79F-EA3FC4D33A23Q35179850-050C1930-15B2-4BE0-99F9-540A052446C4Q35553693-A562C942-B677-4051-9BB7-12E63BD22E1BQ35648897-5FDA6B5B-3267-4FC8-879F-9C264BD85670Q35668795-4BC4AF52-F4EA-4744-9464-07E14B9CA499Q35724830-AAF7A018-332B-4038-A782-6BF820B72034Q35762326-F814F859-8B45-4545-914C-99BC820E1138Q35869542-EB9BD667-F8C9-4641-A4C6-B213A6204480Q35886608-EA4DC02A-B01A-456C-8428-6F997B7CFDC5Q36107291-2FCCDF22-E22A-4D29-AE8D-D80B017C6783Q36778095-EE2E7AE8-CDEF-4AFD-95FA-C453A45DA822Q37130005-3B4E1B70-C32C-41AA-A423-97C29BD2E4CAQ37153759-AAE8F7EF-82DF-42F9-BC47-8B530552BE03Q37610032-C2C97852-5A80-4EF4-8CC2-8D0D50131573Q38058339-154F093A-7658-4617-88D0-A7A0EDCFDD4FQ38201778-308899C2-F011-4963-ABF1-781879E193C1Q38454611-BFE64E85-60FB-41CD-B721-A11220252347Q38633258-3CF31E8C-0AAB-40E8-8297-2871C235A222Q38722698-517EF63A-6CB6-4729-B3F9-417F4F3D73ECQ38755577-CA7E47C3-D748-4056-8958-26A1B3E01A83Q38773844-7048CA0F-BEAA-43AE-BD0B-A5645D41DC36Q38794405-CDF30204-456B-48A3-9051-5366956821D6Q38977291-5036E732-F878-4630-BF3E-E0604BEF5848Q39109051-E89F5572-64F6-4BAA-80B2-7C38B14C0C24Q39113702-B60CC2E5-9432-4A50-AE37-E66506E147ECQ39197925-FC7B3831-4CCA-4BB9-944A-69C6524517B0Q39249797-0A4B16C9-168E-4A8E-A9FA-0043B02AB144Q39325845-90A6ED39-67AF-4635-AA4F-5FEB7162CE26
P2860
Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Serum levels of FGF-21 are inc ...... ted with adverse lipid profile
@ast
Serum levels of FGF-21 are inc ...... ted with adverse lipid profile
@en
type
label
Serum levels of FGF-21 are inc ...... ted with adverse lipid profile
@ast
Serum levels of FGF-21 are inc ...... ted with adverse lipid profile
@en
prefLabel
Serum levels of FGF-21 are inc ...... ted with adverse lipid profile
@ast
Serum levels of FGF-21 are inc ...... ted with adverse lipid profile
@en
P2093
P2860
P1433
P1476
Serum levels of FGF-21 are inc ...... ted with adverse lipid profile
@en
P2093
Shaoqiang Lin
Wenke Feng
Xiaojie Wang
Xiaojing Yin
Xiaokun Li
Xinxin Yan
Yanlong Liu
Zhuofeng Lin
P2860
P304
P356
10.1371/JOURNAL.PONE.0015534
P407
P577
2010-12-29T00:00:00Z